PT-141 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
PT-141 (Bremelanotide) is a Melanocortin receptor agonist. Synthetic α-MSH analog targeting MC1R and MC4R for sexual desire modulation. It is researched for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement. Common dosages range from 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month.
What Is PT-141?
PT-141 (Bremelanotide) is a Melanocortin receptor agonist. Synthetic α-MSH analog targeting MC1R and MC4R for sexual desire modulation. Also known as PT-141, Vyleesi (brand), it has been studied for its potential effects on increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
One of the few FDA-approved peptide therapies and the only medication targeting sexual desire through melanocortin brain pathways rather than vascular mechanisms — treats desire itself, not just physical function. In the research community, PT-141 has gained attention for its distinctive profile.
How Does PT-141 Work?
Activates melanocortin receptors MC1R and MC4R, with MC4R modulating sexual desire through hypothalamic neural circuits. Engages endogenous melanocortin pathways regulating arousal, desire, and sexual response — a completely different mechanism than PDE5 inhibitors like sildenafil.
This multi-pathway activity helps explain why PT-141 shows potential across several different applications.
What Does the Research Say About PT-141?
FDA approved in 2019 based on two Phase 3 trials with 1,267+ premenopausal women showing significant improvements in sexual desire and reduced distress. Well-established safety and efficacy profile.
Researchers should consult the latest peer-reviewed literature for the most current findings.
What Is the Recommended PT-141 Dosage?
Standard PT-141 dosing: 1.75 mg per dose (FDA-approved), administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month via subcutaneous self-injection.
Half-life: peak effects 15-30 minutes post-injection. Cycle length: on-demand acute dosing; no continuous cycle required.
Use our peptide dosing calculator for exact reconstitution ratios.
Calculate Your PT-141 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PT-141.
Open Calculator →What Are the Side Effects of PT-141?
Nausea (40% incidence, especially first injection), flushing (20%), injection site reactions (13%), headache (11%). Transient blood pressure increases (2-3 mmHg average). Contraindicated in uncontrolled hypertension.
PT-141 is fda-approved (2019) as vyleesi for hypoactive sexual desire disorder in premenopausal women. prescription medication. off-label use for males by some providers.
Can You Stack PT-141 With Other Peptides?
Works through a unique mechanism distinct from PDE5 inhibitors; not typically combined with other sexual enhancement agents.
What Is the Bottom Line on PT-141?
PT-141 is a Melanocortin receptor agonist researched for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement. Standard protocols use 1.75 mg per dose (FDA-approved) on-demand, 45 minutes before anticipated activity; maximum 8 doses per month for on-demand acute dosing; no continuous cycle required.
Source from COA-tested vendors. Read our beginner's guide for more, or use the dosing calculator to plan your protocol.
Complete Guide
PT-141 (Bremelanotide): Research
Related Reading
- PT-141 Dosage Guide
- PT-141 Benefits
- PT-141 Side Effects
- PT-141 Stacking Guide
- PT-141 Cycle Guide
- PT-141 Research
Research-Grade Sourcing
If you're going to research PT-141, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a Melanocortin receptor agonist. Synthetic α-MSH analog targeting MC1R and MC4R for sexual desire modulation. It is researched for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
What is the recommended PT-141 dosage?
Common dosages: 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month via subcutaneous self-injection. Cycle length: on-demand acute dosing; no continuous cycle required. Half-life: peak effects 15-30 minutes post-injection. Use our peptide calculator for exact reconstitution math.
What are the side effects of PT-141?
Nausea (40% incidence, especially first injection), flushing (20%), injection site reactions (13%), headache (11%). Transient blood pressure increases (2-3 mmHg average). Contraindicated in uncontrolled hypertension.
Is PT-141 safe?
PT-141 has shown a preliminary safety profile in research. FDA-approved (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Prescription medication. Off-label use for males by some providers. All research should follow appropriate safety protocols.